SUMMARY POINTS •  End stage renal disease (ESRD) is a life-threatening condition that results in most patients requiring a lifetime of high cost renal dialysis •  Governments have grappled with the political, economic, and ethical challenges of providing treatment with their available budgets •

Abstract Background Home dialysis (HoD) remains underutilized, despite evidence showing it provides comparable mortality rates to in-center hemodialysis (ICHD) while offering advantages such as improved quality of life and lower overall costs. This scoping review comprehensively evaluates the

Summary Medicines expenditure consumes a significant proportion of public health expenditure in Thailand, where Universal Health Coverage has been in place since 2002. The National List of Essential Medicines has been successfully used as a pharmaceutical benefits package for all public health plan

Abstract: There is increasing impetus to use pharmaceutical interventions, ie, ranibizumab or bevacizumab, for the treatment of particular macular diseases. This paper describes the evidence and decision-making of the National List of Essential Medicines Committee that recently announced the inclusi

Doctors were told last month that we should stop doing so many screenings for prostate cancer with the prostate-specific antigen test. We learned that sigmoidoscopy is a cheaper, easier and effective alternative to colonoscopy for colon cancer screening. And a study I led turned up strong evidence t

Antimicrobial resistance (AMR) will continue to significantly impact healthcare and public health around the world. Given the complexity of AMR and the multi-dimensional nature of its aetiology and impact, a multi-sectoral and inter-disciplinary approach is required to mitigate its impact. “One Health” is an approach to designing and implementi

HPV vaccination policy in Thailand had been largely driven by the unaffordable prices of vaccine products. Although domestic HTA in formation, including health economic data of intervention, had been available, such evidence play a limited role in HPV vaccination policy formulation. Existing cost-effectiveness studies have resulted in efforts to im